[Antibacterial therapy of urinary tract infections. Results of a clinical trial with the combination sulfamoxol/Trimethoprim (= CN 3123) (author's transl)]. / Antibakterielle Therapie von Harnwegs-infektionen Ergebnisse einer klinischen Prüfung mit der Kombination Sulfamoxol/Trimethoprim (= CN 3123)

In the present paper, the use of the combination preparation sulfamoxol/trimethoprim (CN 3123, Nevin [Grünenthal], Supristol [Nordmark]) in urinary tract infections is reported. This preparation was used in 165 patients of both sexes and all ages. The initial dose was 2 tablets followed by a maintenance dose of 1 tablet every 12 hours for a treatment lasting 10 days on the average. The preparation led to asepsis in 69% of the patients with chronic urinary tract infections if the organisms were sensitive in vitro. In asymptomatical urinary tract infections complicated by fistula and transurethral indwelling catheters, on the other hand, elimination of organisms was only attained in 46%. In our opinion, antibiotic therapy is not indicated in these patients only after taking off the indwelling catheter.

[Efficacy and tolerance of trimethoprim sulfamoxole combination in childhood (author's transl)]. / -Sulfamoxol--Sllfamoxol-

CN 3123 was tested in 4 hospitals on 257 children, 218 of whom were included in the evaluation of the success of therapy. It was administered for the treatment of urinary tract infections (n = 125), bronchial infections (n = 24), intestinal infections (n = 25) and ENT infections (n = 37). The results indicated that, with a failure rate of only 7%, the drug was successfully employed. Tolerance to the medicament was good. Vomiting occurred in 7 children (2.7%) and allergic skin reactions were observed in 6 children (2.3%). A comparative study of CN 3123 and Co-trimoxazole showed the same efficacy and tolerance for both medicaments.

[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Sixth communication: Results of compatibility of CN 3123 (author's transl)]. / Klinische Prüfung der antibakteriellen Kombination Sulfamoxol/Trimethoprim (CN 3123). 6. Mitteilung: Ergebnisse zur Verträglichkeit von CN 3123

1. During the clinical trial of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) side-effects were reported in only 56 (=4.1%) of the 1371 patients who took part. 2. The numerous laboratory parameters studied in the whole group and in the group which received long-term treatment did not show any significant changes due to CN 3123. 3. The frequency and the type of side-effects which occurred under the combined preparation CN 3123 were the same as those known to be caused by sulfonamide treatment. 4. The good tolerance, which is a familial feature of sulfonamide treatment, is not impaired when sulfamoxole is combined with trimethoprim.

[Pharmacological investigations with the combination sulfamoxole/trimethoprim, a new broadspectrum chemotherapeutic agent (author's transl)]. / Pharmakologische Untersuchungen zur Verträglichkeit der Kombination Sulfamoxol/Trimethoprim (CN 3123), eines neuen Breitbandchemotherapeutikums

Investigations were conducted with the combination of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) in a dose ratio of 5:1, with respect to pharmacological activity and possible side effects. The effects obtained with the combination CN 3123 were compared with those of the single substances. In a dose range comparable to that as used in clinical treatment, there were no effects on cardiovascular or respiratory functions, on functions of autonomic and central nervous system, on contractility of smooth muscles and on data of clinical chemistry such as urine and electrolyte excretion, blood sugar, blood coagulation and liver function tests. Doses which are 5 to 10 times higher than the initial dose or 10 to 20 times higher than the maintenance dose used in man caused an increase of urine and sodium excretion without influencing potassium and chloride output. There were no signs of sedation as alteration of motility or EEG patterns, but in mice and rats there was an increase in both duration and depth of anaesthesia caused by barbiturates or ether. Only in a dose range 30 to 40 times higher than the initial dose for man there were some slight alterations with respect to cardiovascular system and liver function tests. In vitro, with high concentrations of CN 3123 there was a weak, unspecific spasmolytic effect on the isolated ureter and an increase in the refractory period of the guinea pig atrium. There were no hints that the side effects seen with separate administration of high or very high doses of sulfamoxole or trimethoprim were increased or poteniated by their simultaneous administration. Slight side effects in animals were only observed with doses exceeding the tenfold of the doses for therapeutic use in men. Therefore, the therapeutic range of CN 3123 seems to be more than adequate.